Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Suicide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    363 result(s) found for: Suicide. Displaying page 9 of 19.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2010-024320-23 Sponsor Protocol Number: I4F-EW-CCAC Start Date*: 2011-03-08
    Sponsor Name:Chorus, Eli Lilly and Company
    Full Title: A Proof-of-Concept Study of the Effects of LY2828360 in the Treatment of Patients with Osteoarthritic Knee Pain
    Medical condition: Pain in osteoarthritic knee.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10018065 - General disorders and administration site conditions 10049475 Chronic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-004276-35 Sponsor Protocol Number: PI-0290-2012 Start Date*: 2014-10-10
    Sponsor Name:Hospital Regional Universitario. IBIMA
    Full Title: Phase II, Double-blind, randomized, 1-way cross-over, to investigate the effectiveness of the combination of ascorbic acid (vitamin C) and tocopherol (vitamin E) versus placebo for the treatment of...
    Medical condition: The trial aims to treat depression. The incidence of major depression in the elderly accounts for between 3.6 and 4.8% and increases to 8 to 37.4% when depressive disorders in general is studied. B...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002577-22 Sponsor Protocol Number: COMP003 Start Date*: Information not available in EudraCT
    Sponsor Name:COMPASS Pathfinder, Limited
    Full Title: The safety and efficacy of psilocybin as an adjunctive therapy in participants with treatment-resistant depression
    Medical condition: treatment resistant depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    21.1 100000004873 10025463 Major depressive disorder, single episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003313-34 Sponsor Protocol Number: SPD489-345 Start Date*: 2013-03-28
    Sponsor Name:Shire Development LLC
    Full Title: A Phase 3, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults with Binge Eating Disorder
    Medical condition: Binge eating disorder is characterized by recurrent, distressing episodes of uncontrolled consumption of large amounts of food (binge eating) without the inappropriate compensatory weight loss beha...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000163-89 Sponsor Protocol Number: COG0104 Start Date*: 2018-04-23
    Sponsor Name:Cognition Therapeutics, Inc.
    Full Title: A Pilot Study to Evaluate the Effect of CT1812 Treatment on Aβ Oligomer Displacement into CSF in Subjects with Mild to Moderate Alzheimer's Disease Followed by a Six-Month Open Label Extension of a...
    Medical condition: Sponsor is developing an oral formulation of CT1812 fumarate to treat AD and mild cognitive impairment.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000813-19 Sponsor Protocol Number: EURE-CART-1 Start Date*: 2019-09-04
    Sponsor Name:MolMed S.p.A.
    Full Title: A Phase I-IIa trial to assess the safety and antitumor activity of autologous CD44v6 CAR T-cells in acute myeloid leukemia and multiple myeloma expressing CD44v6.
    Medical condition: Acute myeloid leukemia and Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003018-17 Sponsor Protocol Number: SPD489-322 Start Date*: 2012-10-10
    Sponsor Name:Shire Development LLC
    Full Title: The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-003252-20 Sponsor Protocol Number: ACP-103-055 Start Date*: 2019-06-11
    Sponsor Name:ACADIA Pharmaceuticals Inc
    Full Title: A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SK (Prematurely Ended) PL (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004897-40 Sponsor Protocol Number: GABA-2 Start Date*: Information not available in EudraCT
    Sponsor Name:PHARM – Pharmaceutical Research Management srl
    Full Title: Randomized, double-blind, placebo controlled, multi-centre, superiority phase II study to evaluate the safety, pharmacokinetic, efficacy of gabapentin liquid formulation as add-on to morphine in ch...
    Medical condition: Chronic pain of neuropathic or mixed origin
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004852 10054095 Neuropathic pain LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Ongoing) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-006012-24 Sponsor Protocol Number: NBI-827104-ET2016 Start Date*: 2021-04-06
    Sponsor Name:Neurocrine Biosciences
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of NBI-827104 in Subjects with Essential Tremor
    Medical condition: Essential tremor
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10015496 Essential tremor PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-006053-22 Sponsor Protocol Number: NLX-112-DYS-101 Start Date*: 2021-09-22
    Sponsor Name:Neurolixis SAS
    Full Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 versus Placebo in Levodopa-induced Dyskinesia in Parkinson’s Disease
    Medical condition: Parkinson´s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001807-19 Sponsor Protocol Number: TV50717-CNS-30081 Start Date*: 2019-11-12
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP)
    Medical condition: Dyskinesia in cerebral palsy (DCP)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10068804 Athetoid cerebral palsy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Prematurely Ended) DK (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000567-77 Sponsor Protocol Number: 42847922MDD1016 Start Date*: 2021-05-19
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Short-term Exploratory Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have ...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA ES (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004351-23 Sponsor Protocol Number: I5Q-MC-CGAS Start Date*: 2021-02-22
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – the REBUILD-1 Study
    Medical condition: Episodic Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027602 Migraine headache LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) DE (Completed) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003024-41 Sponsor Protocol Number: 20190531 Start Date*: 2023-01-25
    Sponsor Name:Amgen Inc
    Full Title: A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet’s Disease or 5 Years of Age or Older With Juv...
    Medical condition: Subjects with active Behçet's Disease or Juvenile Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10004212 Behcet's disease LLT
    20.0 100000004859 10079454 Systemic juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Not Authorised) IT (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001098-55 Sponsor Protocol Number: MMED007 Start Date*: 2021-11-24
    Sponsor Name:Mind Medicine, Inc.
    Full Title: Safety and efficacy of repeated low dose D-lysergic acid diethylamide (LSD) D-Tartrate (MM-120) as treatment for ADHD in adults: a multi-center, randomized, double- blind, placebo-controlled Phase ...
    Medical condition: Attention-Deficit/Hyperactivity Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003524-20 Sponsor Protocol Number: BP41316 Start Date*: 2020-12-15
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A phase II multicenter, randomized, double-blind, 12-week treatment, 3-arm, parallel-group, placebo-controlled study to investigate the efficacy, safety and tolerability of RO7017773 in participant...
    Medical condition: Autism Spectrum Disorder (ASD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003984-24 Sponsor Protocol Number: EPIsoDE_01 Start Date*: 2020-11-17
    Sponsor Name:Central Institute of Mental Health
    Full Title: A phase II randomized, double-blind, active placebo-controlled parallel group trial to examine the efficacy and safety of psilocybin in treatment-resistant major depression
    Medical condition: Treatment-Resistant Depressive Episode or Treatment-Resistant Recurrent Depressive Disorder of moderate to severe degree withoutpsychotic features
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002226-23 Sponsor Protocol Number: 2013-002226-23 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Bergen, Department of Global Public Health and Primary Care
    Full Title: Efficacy of Pain Treatment on Depression in Patients with Dementia. A Randomized Clinical Trial of Efficacy
    Medical condition: Depression Pain Dementia
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000305-24 Sponsor Protocol Number: AN01AC11 Start Date*: 2021-03-18
    Sponsor Name:Anebulo pharmaceuticals, Inc.
    Full Title: A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of CB1 antagonist ANEB-001 in healthy occasional ...
    Medical condition: THC intoxication
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 16:17:49 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA